Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Jun 20, 2012 |
referred to rules delivered to senate passed assembly ordered to third reading rules cal.470 rules report cal.470 reported reported referred to rules |
Feb 14, 2012 |
reported referred to ways and means |
Jan 04, 2012 |
referred to health |
Jun 15, 2011 |
print number 6039a |
Jun 15, 2011 |
amend (t) and recommit to ways and means |
Jun 13, 2011 |
reported referred to ways and means |
Jun 07, 2011 |
reference changed to health |
Mar 04, 2011 |
referred to insurance |
Assembly Bill A6039
2011-2012 Legislative Session
Sponsored By
KELLNER
Archive: Last Bill Status - In Senate Committee Rules Committee
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
Bill Amendments
co-Sponsors
Harry B. Bronson
Clifford Crouch
multi-Sponsors
Brian F. Curran
John McEneny
2011-A6039 - Details
- Current Committee:
- Senate Rules
- Law Section:
- Public Health Law
- Laws Affected:
- Amd §2510, Pub Health L; amd §369-ee, Soc Serv L; amd §4326, Ins L
- Versions Introduced in 2013-2014 Legislative Session:
-
A962
2011-A6039 - Summary
Provides that persons with hemophilia and other clotting protein deficiencies who are otherwise eligible for the Child Health Plus or Family Health Plus program shall have access to reimbursement for outpatient blood clotting factor concentrates and other necessary treatments and services.
2011-A6039 - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 6039 2011-2012 Regular Sessions I N A S S E M B L Y March 4, 2011 ___________ Introduced by M. of A. KELLNER -- read once and referred to the Commit- tee on Insurance AN ACT to amend the public health law, the social services law and the insurance law, in relation to providing that persons with hemophilia and other clotting protein deficiencies who are otherwise eligible for the Child Health Plus, Family Health Plus, and Healthy New York programs shall have access to reimbursement for outpatient blood clot- ting factor concentrates and other necessary treatments and services THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Legislative findings. Hemophilia is a rare hereditary bleeding disorder resulting from a deficiency in blood proteins known as clotting factors. Without an adequate supply of clotting factors, indi- viduals can experience prolonged bleeding following routine medical and dental procedures, trauma, and a range of physical activities. Addi- tionally, individuals with hemophilia often experience spontaneous internal bleeding that can cause severe joint damage, chronic pain, and even death. Prior to the 1970s, individuals with hemophilia seldom lived beyond the age of 30 years. Early treatment consisted of whole blood and plasma transfusions at hospitals. These treatments were difficult, time consum- ing and only minimally effective. The advent of commercially prepared blood clotting factors in the 1980s represented a major advance in treatment, both in terms of efficacy and convenience. Most importantly, these advances allowed for home infusion. In addition to hemophilia, there are several other disorders resulting from blood protein deficiencies. These include Von Willebrand Disease (VWD), the most common bleeding disorder, affecting approximately two million Americans. Individuals with the severest form of VWD rely on clotting factor treatments similar to those used by individuals with hemophilia. EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD09788-01-1
co-Sponsors
Harry B. Bronson
Clifford Crouch
Gary Finch
multi-Sponsors
Brian F. Curran
Michael Cusick
Andrew Hevesi
Donna Lupardo
2011-A6039A (ACTIVE) - Details
- Current Committee:
- Senate Rules
- Law Section:
- Public Health Law
- Laws Affected:
- Amd §2510, Pub Health L; amd §369-ee, Soc Serv L; amd §4326, Ins L
- Versions Introduced in 2013-2014 Legislative Session:
-
A962
2011-A6039A (ACTIVE) - Summary
Provides that persons with hemophilia and other clotting protein deficiencies who are otherwise eligible for the Child Health Plus or Family Health Plus program shall have access to reimbursement for outpatient blood clotting factor concentrates and other necessary treatments and services.
2011-A6039A (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 6039--A 2011-2012 Regular Sessions I N A S S E M B L Y March 4, 2011 ___________ Introduced by M. of A. KELLNER, BRONSON, CROUCH -- Multi-Sponsored by -- M. of A. CURRAN, McENENY -- read once and referred to the Committee on Insurance -- reported and referred to the Committee on Ways and Means -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee AN ACT to amend the public health law, the social services law and the insurance law, in relation to providing that persons with hemophilia and other clotting protein deficiencies who are otherwise eligible for the Child Health Plus or Family Health Plus programs shall have access to reimbursement for outpatient blood clotting factor concentrates and other necessary treatments and services THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Legislative findings. Hemophilia is a rare hereditary bleeding disorder resulting from a deficiency in blood proteins known as clotting factors. Without an adequate supply of clotting factors, indi- viduals can experience prolonged bleeding following routine medical and dental procedures, trauma, and a range of physical activities. Addi- tionally, individuals with hemophilia often experience spontaneous internal bleeding that can cause severe joint damage, chronic pain, and even death. Prior to the 1970s, individuals with hemophilia seldom lived beyond the age of 30 years. Early treatment consisted of whole blood and plasma transfusions at hospitals. These treatments were difficult, time consum- ing and only minimally effective. The advent of commercially prepared blood clotting factors in the 1980s represented a major advance in treatment, both in terms of efficacy and convenience. Most importantly, these advances allowed for home infusion. In addition to hemophilia, there are several other disorders resulting from blood protein deficiencies. These include Von Willebrand Disease (VWD), the most common bleeding disorder, affecting approximately two EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD09788-03-1
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.